Rejected from Science Immunology? The 6 Best Journals to Submit Next

Source: Clarivate JCR 2024; journal author guidelines and open-access pages, accessed June 2026.

The same shortlist by the numbers, so you can place each option against Science Immunology's standing (JCR 2024 IF 16.3, Q1, rank 6/183):

Source: Clarivate JCR 2024; journal acceptance figures from author guidelines and editorial reports, accessed June 2026.

Immunity is the most natural mechanistic redirect. It rewards comprehensive, multi-system causal stories. If Science Immunology liked the biology but wanted more breadth, Immunity may value the depth instead, provided the mechanism is complete.

Nature Immunology sits a step higher on flagship consequence. Send your paper here when the result is even broader or sharper at the top end, not when Science Immunology already said the reach was thin.

Journal of Experimental Medicine is a high-trust, scholar-led venue for disease-mechanism and experimental-medicine immunology. Its acceptance odds are friendlier and its first decisions are fast.

Science Advances is the cleanest transfer landing inside the AAAS family. A substantive but not paradigm-defining advance with an open-access preference fits here, and the transfer keeps your editorial history intact.

Cell Reports Medicine suits translational immunology that is directly relevant to human health and disease. Nature Communications is the broad-scope catch-all when the paper travels across disciplines.

Science Immunology sits inside the AAAS Science family, and the editor reads your cover letter partly to decide where the paper belongs. The Science-family transfer system lets editors offer to move a rejected manuscript to a sibling journal without a fresh start, preserving editorial history and any referee reports inside one submission system.

The realistic ladder after Science Immunology:

• Tier 1, same family: Science Advances is the next-tier AAAS venue and accepts transfers from Science Immunology. If you were offered a transfer, take it seriously; it is faster than starting over. If broad enough, Science itself is the upward route, and Science Translational Medicine fits a translational-dominant story.

• Tier 1, sibling immunology venues: Immunity (Cell Press) and Nature Immunology (Nature Portfolio) are lateral moves at comparable or higher selectivity.

Choose these only if the rejection was about breadth, not a fixable mechanism gap.

• Tier 2, friendlier odds: Journal of Experimental Medicine and Cell Reports Medicine step down on selectivity while keeping a strong specialist or translational audience.

• Tier 2, broad open access: Nature Communications and Science Advances both take cross-disciplinary work that does not need an immunology-specialist screen.

The discipline that matters: do not cascade a paper down the ladder unchanged if the rejection named a real gap. A transfer to a friendlier venue still meets reviewers who will flag the same problem. Reframe for breadth when the issue was scope; fix the science when the issue was substance.

In our pre-submission review work with Science Immunology submissions, four patterns generate the most consistent desk rejections, and knowing them tells you what to change before the next venue sees the paper.

The advance is real but too narrow for a Science-family screen. This is the single most common pattern we see in Science Immunology submissions. The data are often excellent, but the abstract and cover letter argue importance inside one specialist readership without connecting the result to a broad immunology consequence. Science Immunology routes by breadth, so a paper that reads as specialist-only becomes a transfer candidate before it reaches review.

The testable fix: name, in the significance paragraph, a second immunology subcommunity that would change how it thinks because of this result. If you cannot name one honestly, the paper belongs at Immunity, Nature Immunology, or JEM instead, where mechanistic depth outranks field-wide reach.

Phenotyping outruns mechanism. We repeatedly see Science Immunology manuscripts where the figures describe a striking immune phenotype but the methods never close the causal loop on why it happens. A descriptive immune-cell atlas or a correlation between a cell state and an outcome reads as interesting biology, but Science Immunology and Immunity both expect mechanistic closure. Check whether your central claim survives a reviewer asking "what is the causal experiment?"

If the answer is a loss-of-function or gain-of-function control you have not run, that is the gap reviewers at the next mechanistic journal will name too.

The significance claim is broader than the evidence. A recurring pattern in our Science Immunology reviews is a significance statement that asserts field-wide impact the data do not yet support, often with a single model system. Editors test that claim in the first minute. When the reach in the title overstates the results, the paper draws skepticism rather than enthusiasm. The fix is to match the claimed breadth to the evidence, or to add the orthogonal validation in a second system that earns the broader claim.

Missing controls and statistical detail visible at the desk. Science-family editors screen the figures and statistical analysis plan for absent controls, underpowered sample sizes, and tests mismatched to the data structure before assigning peer review. We see this in Science Immunology submissions where the immunology is sound but the quantification is thin: no uncertainty on key panels, no stated power analysis, or a flow-cytometry gating strategy left out of the supplementary materials.

These are fixable, and fixing them before resubmission to Immunity or JEM removes an easy reason to reject.

The reflex after a Science Immunology rejection is to blast the paper down the ladder unchanged. Resist it. Don't just resubmit to a friendlier venue; reviewers there will still see the same gap that cost you here.

Separate the two failure types honestly. If the rejection was a scope or framing decision, the science is fine and the work is reframing the significance case for the new journal: do not run new experiments you do not need. If the rejection cited a mechanism gap, a missing control, or thin statistics, that is real work, and no amount of reframing hides it from the next reviewer.

When to consider an appeal: rarely. Science Immunology desk decisions are fast and editorial, and appeals succeed only when you can show a clear factual error in the assessment. In almost every case, targeting a better-fit journal moves faster than contesting the decision. The honest path is usually down or sideways, with the paper improved, not just re-addressed.

Submit to the next journal if:

• the rejection cited breadth or scope, not a fixable flaw, and the new venue rewards depth
• you can reframe the significance case for the target journal's bar in days
• the data already answer the obvious "what is the causal experiment?" question

Think twice and fix first if:

• a reviewer named a missing control or a thin statistical analysis on a key figure
• the central claim rests on one model system without orthogonal validation
• the abstract still overstates field-wide reach the results do not support

We checked the AAAS instructions for authors and the Science family-of-journals pages for Science Immunology's scope, transfer system, and editorial screen, and the Clarivate JCR 2024 rows for every journal in the shortlist. The editorial framing comes from the patterns we see in our pre-submission review work with immunology submissions, not from a private AAAS account. Use this page to decide where the manuscript goes next after a Science Immunology rejection; for upload mechanics and timing, use the submission guide linked below.